enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.
Company profile
Ticker
RENB
Exchange
Website
CEO
Eric Leire
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DanDrit Biotech USA, Inc., Enochian Biosciences Inc, Putnam Hills Corp.
SEC CIK
Corporate docs
Subsidiaries
Renovaro Biopharma, Inc. • Renovaro Biosciences Denmark ApS • Renovaro Technologies, Inc. ...
RENB stock data
Latest filings (excl ownership)
8-K
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
24 Apr 24
8-K/A
Financial Statements and Exhibits
24 Apr 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
8-K
Termination of a Material Definitive Agreement
7 Mar 24
8-K
Departure of Directors or Certain Officers
5 Mar 24
D
Exempt offering of security
23 Feb 24
8-K
Other Events
16 Feb 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
7 Feb 24
Latest ownership filings
SC 13D/A
William Anderson Wittekind
8 Apr 24
4
JAMES SAPIRSTEIN
19 Mar 24
4
Simon Tarsh
13 Mar 24
3
Simon Tarsh
13 Mar 24
4
Carol L Brosgart
28 Feb 24
3
Karen Brink
23 Feb 24
4
Rene Sindlev
22 Feb 24
SC 13G/A
Abildgaard Ole
22 Feb 24
4
Ole Abildgaard
20 Feb 24
SC 13D/A
William Anderson Wittekind
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 523.47 k | 523.47 k | 523.47 k | 523.47 k | 523.47 k | 523.47 k |
Cash burn (monthly) | 450.34 k | 620.70 k | 3.06 mm | 3.38 mm | 925.74 k | 991.51 k |
Cash used (since last report) | 3.11 mm | 4.29 mm | 21.12 mm | 23.33 mm | 6.39 mm | 6.85 mm |
Cash remaining | -2.59 mm | -3.76 mm | -20.60 mm | -22.81 mm | -5.87 mm | -6.32 mm |
Runway (months of cash) | -5.7 | -6.1 | -6.7 | -6.8 | -6.3 | -6.4 |
Institutional ownership, Q2 2023
16.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 39 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 20.28 mm |
Total shares | 23.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Anderson Wittekind William | 18.96 mm | $20.28 mm |
Abildgaard Ole | 5.01 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Simon Tarsh | Option to purchase shares of common stock Common Stock | Grant | Acquire A | No | No | 2.98 | 10,000 | 29.80 k | 10,000 |
6 Mar 24 | Sapirstein James | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 2.66 | 28,196 | 75.00 k | 28,196 |
20 Feb 24 | Rene Sindlev | Common Stock | Acquire X | Yes | No | 0.53 | 471,699 | 250.00 k | 13,605,297 | |
20 Feb 24 | Rene Sindlev | Warrant Common Stock | Dispose X | Yes | No | 0.53 | 471,699 | 250.00 k | 471,698 | |
13 Feb 24 | Rene Sindlev | Common Stock | Conversion | Acquire C | Yes | No | 0 | 701,260 | 0.00 | 13,133,598 |
13 Feb 24 | Rene Sindlev | Series A Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 70,126 | 0.00 | 0 |
News
RenovaroCube To Acquire 100% Ownership Of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership; Financial Terms Not Disclosed
24 Apr 24
Renovaro Announces The Appointment Of Professor Dr. Geert Kazemier As The Chairman Of Its Scientific Advisory Board
18 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
14 Mar 24
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
4 Mar 24
Hit With Short Seller Report, Renovaro Biosciences Comments On Hindenburg's Opinion Piece
14 Feb 24
Press releases
Trailblazing AI Driven Early Cancer Diagnostics and Therapeutics for Detection with Nvidia Super Computing Power; Acquiring 100% Ownership of Cyclomics; Renovaro Inc. (Nasdaq: RENB)
25 Apr 24
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
18 Apr 24
Sending the Bears back into Hibernation with these 3 potential Short Squeeze Stocks
20 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENB
11 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENB
7 Mar 24